Human B3GNT2 Stable Cell Line - A375

The B3GNT2 gene encodes a highly conserved enzyme: UDP-GlcNAc:βGal β-1,3-N-acetylglucosaminyltransferase 2 (B3GNT2)—a critical glycosyltransferase localized within the Golgi apparatus. This enzyme is primarily responsible for initiating and extending poly-N-acetyllactosamine chains on N-linked glycans, O-linked glycans, and glycosphingolipids. By catalyzing the transfer of N-acetylglucosamine to terminal galactose residues via β-1,3 glycosidic linkages, B3GNT2 plays a foundational and indispensable role in establishing the structural complexity of the cellular glycome. The intricate glycosylation modifications mediated by this specific enzyme are pivotal to a wide array of physiological and pathological processes, including cell adhesion, tissue development, molecular transport, and complex signal transduction pathways. In recent years, the B3GNT2 gene has garnered widespread and growing attention within the fields of oncology and tumor immunology, given its significant role in regulating mechanisms of immune evasion. Studies have confirmed that alterations in—or the persistent upregulation of—B3GNT2 expression within malignant tissues can directly modulate the glycosylation status of key immune checkpoint molecules and various cell surface receptors. This aberrant glycosylation profile not only severely suppresses T-cell activation and significantly accelerates T-cell exhaustion but also profoundly facilitates pathological interactions between tumor cells and immunosuppressive lectins (such as galectins) enriched within the tumor microenvironment.

The human B3GNT2 stable cell line, established within the A375 cellular background, has been meticulously designed and constructed to advance our in-depth understanding of this critical glycosyltransferase in the context of malignant melanoma. A375 is a well-characterized and widely utilized human malignant melanoma cell line, renowned for its aggressive growth characteristics and its significant clinical relevance in the study of skin cancer biology. By stably integrating the human B3GNT2 gene into the genome of the A375 cell line, this specialized cell line ensures robust, consistent, and long-term expression of the B3GNT2 protein, thereby effectively overcoming the inherent issues of transience and reproducibility associated with traditional plasmid transfection methods. Researchers can leverage this stable B3GNT2-A375 cell line to conduct in-depth investigations into the specific downstream biological effects that B3GNT2-mediated glycosylation modifications exert on the proliferation, invasive potential, and metastatic capabilities of melanoma cells. In the realm of therapeutic drug development, this genetically engineered cell line is particularly well-suited for high-throughput pharmacological screening, enabling researchers to precisely identify and validate novel B3GNT2 enzyme inhibitors or therapeutic antibodies targeting specific glycosylated surface antigens.